GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Debt-to-Asset

Kuros Biosciences (XSWX:KURN) Debt-to-Asset : 0.03 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Debt-to-Asset?

Kuros Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.58 Mil. Kuros Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF1.57 Mil. Kuros Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was CHF71.46 Mil. Kuros Biosciences's debt to asset for the quarter that ended in Dec. 2023 was 0.03.


Kuros Biosciences Debt-to-Asset Historical Data

The historical data trend for Kuros Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Debt-to-Asset Chart

Kuros Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.02 0.02 0.03

Kuros Biosciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.04 0.03

Competitive Comparison of Kuros Biosciences's Debt-to-Asset

For the Medical Devices subindustry, Kuros Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Debt-to-Asset falls into.



Kuros Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kuros Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Kuros Biosciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kuros Biosciences  (XSWX:KURN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Kuros Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences (XSWX:KURN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines